Here, we present evidence that the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) is a major therapeutic target potentially controlling the occurrence and evolution of GA symptoms and that TecfideraTM, administrable per OS, and whose active principle dimethyl fumarate (DMF), which possess antioxidant and immunomodulatory properties via induction of Nrf2 nuclear translocation, appears well suited to be repurposed in patients with the late stage of the dry form of AMD. Here, NFE2L2 is linked to age-related macular degeneration.